Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Beatriz Rey BúaCarlos GrandeJose Javier Sánchez BlancoPau AbrisquetaAntonio GutierrezÁngel R PayerEva GinéIzaskun Zeberio EtxetxipiaMaria José TerolFátima de la Cruz VicenteRafael AndreuMaría José RamírezAdolfo de la FuenteMaría Cruz ViguriaMaría Jesus PeñarrubiaAna Jiménez-UbietoSantiago Montes MorenoArmondo López-GuillermoMaría Dolores CaballeroAlejandro Martin Martin Garcia-SanchoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Ibrutinib in combination with R-GemOx, followed by ibrutinib maintenance, demonstrated encouraging antitumor activity with durable responses and a manageable toxicity in patients with non-GCB DLBCL.